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Exploring the links between peptoid antibacterial
activity and toxicity†‡
H. L. Bolt,a G. A. Eggimann,a C. A. B. Jahoda,b R. N. Zuckermann,c
G. J. Sharples*b and S. L. Cobb*a
Peptoids are a promising class of antimicrobial agents with reported activities against a range of both
Gram-positive and Gram-negative bacteria, fungi and most recently parasites. However, at present the
available toxicity data is somewhat limited and as such rationally designing effective antimicrobial peptoids
can be challenging. Herein, we present the toxicity profiling of a series of linear peptoids against mamma-
lian cell lines (HaCaT and HepG2). The cytotoxicity of the peptoid library has then been correlated with
their antibacterial properties against Gram-positive and Gram-negative bacteria and also to the hydropho-
bicity of the peptoid sequences. The work presented provides valuable data to aid in the future rational de-
sign of antimicrobial peptoids.
The growing prevalence of antibiotic resistance has intensified
demand for novel antimicrobials to replace or complement
existing treatments for infectious diseases. Recent incentives
such as the 10 × '20 Initiative and the Global Antimicrobial
Resistance Research Innovation Fund encourage investment
and a commitment to the development of new antibacterial
drugs.1 Given the effectiveness of the innate immune system
in providing the first line of defence against infection,
considerable research effort has focused on investigating the
activities of antimicrobial peptides (AMPs), with a view to their
deployment as templates for innovative therapeutic design.2–5
AMPs typically contain fewer than 50 amino acids, are cationic
and play a fundamental role in host defence, functioning
as both antimicrobial agents and modulators of the
inflammatory response.6–11 AMPs display potent antimicrobial
activity against a range of clinically important pathogens,
including bacterial, fungal and parasitic species.12–16 However,
despite promising biological properties, AMPs are highly
susceptible to degradation by host proteinases, which has
hindered their exploitation as novel therapeutics including
limited success in clinical trials.2–8,15–19
In the search for peptidomimetics that retain potent anti-
microbial activity yet also exhibit enhanced proteolytic stabil-
ity, α-peptoids (N-substituted glycines) have emerged as
highly promising candidates. In α-peptoids, the side chain of
each residue (monomer) is located on the nitrogen in the am-
ide backbone (Fig. 1). This allows peptoids to keep many of
the advantageous properties of AMPs (e.g. amphilicity) but,
with the inclusion of a tertiary amide backbone, significantly
improve their resistance to enzymatic degradation.20
Peptoids have been shown to have potency against a wide
variety of Gram-positive and negative bacteria,21–30
parasites31–33 and fungi.25,34–36 These studies highlight the
clear potential that peptoids offer as a new class of antimicro-
bials but in order to progress their clinical development a
more detailed study of their toxicity towards mammalian
cells needs to be undertaken.
Peptoid toxicity is often evaluated by haemolytic activity,
however, these assays cannot necessarily be used to predict
toxicity more generally against mammalian cells. For exam-
ple, many peptoids in the literature are based upon peptoid
(NLysNspeNspe)4 (compound 13, Table 1) which exhibits
excellent antimicrobial properties, with a reported selectivity
ratio of >6 and acceptable 50% haemolytic dose (HD50 of 100
μM).23 However, more recently, another publication reports
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in vitro mammalian assays and observed toxicity of peptoid
13 at 5.1 μM against NIH 3T3 murine fibroblasts.37 The Olsen
group have also demonstrated that α-peptide β-peptoid
hybrids show negligible haemolytic activity, but cause severe
membrane alterations to human erythrocytes at low concen-
trations via microscopy.31 Therefore, there is a clear need to
scrutinise the relationship between peptoid antimicrobial
activity and their toxicity towards mammalian cells in greater
detail.
In this study we report the synthesis of one of the largest
single library of antimicrobial peptoids published to date, in
order to undertake a structure–activity relationship (SAR) of
the wide variety of chemical functionalities present. Some of
the sequence motifs and monomers represented here have
not yet been reported in any antibacterial peptoids. This
study focuses on the antibacterial potency of these peptoids
against representative Gram-positive and Gram-negative
species and significantly, we also examine the toxicity of this
library using therapeutic indices against representative mam-
malian cell lines to evaluate the potential of peptoids as
novel anti-infective compounds.
Results and discussion
Library design
We previously described the antiparasitic activities of a small
library of linear peptoids.33 In this work, 18 peptoids from
this first library have been retested to investigate their anti-
bacterial activity and toxicity profiles (peptoids 1–18,
Table 1), which to date have not been reported. An additional
26 novel peptoids were also synthesised to conduct a broader
SAR study (peptoids 19–44, Table 1). This library represents
the largest library of anti-infective peptoids published to our
knowledge.
Since the presumed mode of action of AMPs is by mem-
brane disruption, the peptoid sequences selected contain a
variety of side chain functionalisation to help elucidate the
features necessary for activity. A defined secondary structure
is thought to promote the antimicrobial action of both
peptoids and peptides, therefore all peptoids tested here were
designed around a repeating trimer motif where the third
monomer was typically a cationic monomer (a peptoid helix
turn is reported to occur every three residues in a polyproline
type I helix) and often included the α-chiral Nspe or NĲS-
phenylethyl) glycine monomer in order to help induce an am-
phipathic secondary structure.23,38
All peptoids were either synthesised manually on-resin or
using an automated synthesiser using the submonomer
method of synthesis at room temperature. Compounds be-
tween six and twelve residues in length were made, corre-
sponding to peptoids with an overall positive charge of +2, +3
or +4.39,40 This extended library includes a wide range of
monomers, such as those containing alkyl and substituted
aromatic residues, including chlorinated and fluorinated
peptoids. In addition, we have included peptoids that have
different cationic functionalities in the sequence to further
probe the relationship between charge and activity (Fig. 2).
Previously we described the activity of peptoids that con-
tain lysine monomers (amino-functionalised cationic resi-
dues).32,33 It has been suggested that arginine-containing
peptoids may have increased membrane permeability41 and
so a small number of arginine analogues of our lysine library
were generated. In addition, we recently described the synthe-
sis of peptoids with mixed lysine and arginine functionalities,
which are some of the first examples of this class of com-
pound to be reported in the literature.42
Antimicrobial activity
The activity of our peptoid library was assessed against
both bacterial and mammalian cells to gain a broader
Fig. 2 Peptoid monomers utilised in this study.
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understanding of the factors that lead to effective and selec-
tive antimicrobial peptoids. We screened for broad-spectrum
antibacterial activity against Gram-negative (Escherichia coli
and Pseudomonas aeruginosa) and Gram-positive (Staphylococ-
cus aureus and S. epidermidis) bacteria. The toxicity of the li-
brary was also assessed against two mammalian cell lines;
HaCaT spontaneously transformed aneuploid keratinocytes
were employed to model toxicity against human skin cells
and HepG2, a cell line derived from a human liver carci-
noma, were used as a study on polarised human hepatocytes.
Detailed methods for these assays can be found in the ESI.‡
In order to compare the activity of our compounds be-
tween the minimum inhibitory concentration (MIC) values
obtained for bacteria and the effective dose (ED50) measure-
ments against eukaryotic cells, all results have been
presented in μM units. As seen from the data summarised in
Table 1, many peptoids within the library have low MIC
values against both Gram-negative and Gram-positive bacte-
ria, ranging from the most active at less than 1 μM to inactive
peptoids with no activity even at 100 μM. Some of the MIC
values obtained are within the same range of selected natural
antimicrobial peptides described in the literature. For exam-
ple, the AMP cecropin A was shown to kill 90% of E. coli at
2 μM (ref. 43) and peptoids 33, 34, 35 and 37 all have an MIC
of 6 μM against E. coli. Magainin 2, an amphibian derived
AMP, was reported to have MICs against E. coli, S. epidermidis
and S. aureus of 5 μg mL−1 (2 μM), 10 μg mL−1 (4 μM) and
50 μg mL−1 (20 μM) respectively and many of the peptoids in
Table 1 exhibit even better antibacterial activities.43,44
Unsurprisingly, the activity of most of the peptoids is sig-
nificantly greater against the Gram-positive species (S. aureus
and S. epidermidis) than the Gram-negative E. coli and
P. aeruginosa. This differential activity is probably due to the
presence of the lipopolysaccharide-rich outer membrane of
Gram-negatives, which presents a significant permeability
barrier to many hydrophobic molecules.45,46 Certain com-
pounds within the library displayed selectivity for particular
bacterial species, For example, compound 17 had an MIC of
25 μM against E. coli, but >100 μM against the other Gram-
negative bacterium, P. aeruginosa or 20 which has an MIC of
6 μM against S. epidermidis but only moderate activity of
25 μM against S. aureus. However, no Gram-negative specific
antibacterial peptoids were identified. Any sequences that
can selectively target Gram-negative bacteria are highly sought
after due to rising concerns over antibiotic resistance.47–49
Structure–activity relationships: simple library
Factors necessary for robust activity against the protozoan
intracellular parasite Leishmania mexicana were previously
determined and include sequence length and inclusion of
chiral monomers.31 Side chain length of cationic residues
was also identified as an important feature for efficacy, with
Nae or NLys displaying improved antiparasitic activity over
the longer Nah residue.33 The same features are replicated
here in the activity of the peptoid library against differing
bacterial species. The longest 12 residue peptoids (1, 4, 7, 10,
13 and 16) were always more active than their 9 residue ana-
logues (2, 5, 8, 11, 14 and 17), which were themselves more
active than the 6 residue sequences (i.e. 3, 6, 9, 12, 15 and
18), conclusions that agree with those from the Barron
group.23 Hexapeptoids 3, 6, 9, 12, 15 and 18 showed generally
limited antibacterial activity against the bacteria tested with
MICs of 100 μM, although it is interesting to note that
S. epidermidis did show some increased sensitivity to
peptoids 12 and 15 (Table 1).
Interestingly, the effect of monomer chirality was less
important than with L. mexicana in achieving antibacterial
activity; in many cases, sequences comprised exclusively from
achiral monomers had comparable or better activity than
analogues containing the chiral Nspe building block. For
example, comparing peptoid 4 to 13 which are achiral and
chiral analogues of the same sequence, we observe similar
MIC values against P. aeruginosa (50 μM for both) and
S. aureus (MIC 3 μM and 2 μM). However, against E. coli, the
achiral peptoid 4 has an MIC of 12 μM compared to 25 μM
for the chiral equivalent 13. A similar pattern is apparent
with peptoids 7 and 16 (sequences with Nae and either Nphe
or Nspe respectively), with the peptoids having similar activ-
ity against both P. aeruginosa and S. aureus but the achiral
sequence 7 shows better activity against E. coli (MIC 13 μM
and >100 μM respectively).
When comparing sequences containing different amino-
functionalised cationic monomers, Nae, NLys and Nah, it is
not possible to draw a simple conclusion about the optimum
length of side chain for best antibacterial activity since prom-
ising activity is evident with all three cationic residues.
Peptoids based upon the NxNpheNphe motif 1 (Nah), 4 (NLys)
and 7 (Nae) all have an MIC of 13 μM against E. coli and
good activity against both Staphylococcus species. However,
when comparing the chiral analogues of the same motif
(Nspe replaced Nphe), the sequences with Nah and NLys (10
and 13) have an MIC of 25 μM against E. coli but the peptoid
with the shortest Nae residue (16) has negligible activity. For
peptoids 10, 13 and 16, the activity against P. aeruginosa,
S. aureus and S. epidermidis is similar regardless of the choice
of cationic monomer (Table 1).
Effects of aromatic building block substitution
A selection of substituted aromatic monomers were included
in a similar repeating motif of two aromatic monomers
followed by the charged NLys residue to determine their
impact on biological activity. Monomer substitutions in-
cluded a methoxy group (Npmb), chlorine (Npcb) or fluorine
in both para and meta positions (Npfb, Nmfb). The effect of
these substitutions on anti-Leishmanial activity were reported
recently.32 It was shown that halogenated monomers (in par-
ticular fluorinated ones) improve the efficacy of peptoid
sequences against amastigotes. Based upon the success of
this approach, we concentrated our efforts on the anti-
bacterial screening of halogenated sequences.
MedChemComm Research Article
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Methoxy substituted peptoids were only tested at the lon-
gest 12 residue length (peptoid 19) and show a negligible
effect against the two Gram-negative species and no improve-
ment in action against the Gram-positive bacteria compared
to the unsubstituted analogue (peptoid 4). Addition of
chlorine in the para position improves activity against
L. mexicana axenic amastigotes, however decreases anti-
bacterial activity (i.e. compounds 20 cf. 4 with an MIC of
>100 μM and 13 μM with E. coli) and also significantly
increases the toxicity of the sequences to mammalian cells
(ED50 HepG2 22 μM and >100 μM respectively).
Fluorinated peptoid sequences were more successful at
targeting the various bacteria. Peptoids with exclusively achi-
ral monomers (Npfb or Nmfb) and those with a mixture of
chiral and achiral building blocks (Npfb and Nspe) were
tested. Those sequences containing the achiral monomers
(peptoids 22–25) have marginally improved antibacterial ac-
tivities compared to analogues of the same length with Nphe
rather than fluorinated monomers (peptoids 4–6). There
seems to be no significant difference between monomers
substituted in the para or meta position. Interestingly, the
9-residue peptoids 23 and 25 have a similar level of broad
spectrum antibacterial activity as those with 12 residues (22
and 24), but the former show reduced toxicity to mammalian
cells. The 6-residue sequences display reduced activity
against bacteria. In this case, it appears that the shorter
9-residue sequences 23 and 25 may prove to be better anti-
bacterial candidates with a larger therapeutic window be-
tween activity and toxicity (Table 1)
The simple chiral sequences (i.e. 13) are more potent, but
also more toxic than the achiral Nphe peptoids (4–6). Given
that the fluorinated, achiral monomers exhibit an increase in
antibacterial activity compared to the unsubstituted ana-
logues, the Npfb monomer was also placed into the following
motif: NLysNpfbNspe to examine whether the activity of
chiral sequences could be modulated (peptoids 26 and 27).
Further iterations were also synthesised where the Npfb and
Nspe monomers were placed in a coblock manner (i.e.
sequences 28 and 29). In both templates, the longest
sequences showed the best broad-spectrum antibacterial
activity. In particular, the 12-residue block peptoid (28) is
promising, with reduced toxicity compared to sequences
made of Nspe or Npfb exclusively and improved activity
against E. coli (MIC 6 μM), S. aureus and S. epidermidis
(MICs 2 μM and <1 μM).
Peptoids containing alkyl chains
To probe the relationship between net charge and hydropho-
bicity of a peptoid and its biological activity, analogues of
peptoid 13 were synthesised where the cationic NLys mono-
mer was substituted by the alkyl monomer Namy. By replac-
ing the charged amino group with a methyl group, the overall
compound charge is reduced, however the number of atoms
in the side chain and overall molecular weight remains
unaltered. In these analogues (peptoids 30–32), the charge is
replaced at just the N terminal end of the sequence or at two
positions within the sequence.
When the antibacterial properties are considered, there is
little difference in efficacy against the Gram-positive bacteria
tested, however, the substitutions lead to a reduction in over-
all activity against Gram-negatives. The parent sequence 13
shows moderate activity against E. coli and P. aeruginosa
(MICs of 25 μM and 50 μM respectively) and potent micromo-
lar activity against the Gram-positives. However, peptoids
30–32 have MICs of 50 μM or >100 μM against E. coli and
similar reductions in activity are seen for P. aeuriginosa.
Substitution of arginine-instead of lysine-residues
As described in the literature,31,41,50 arginine-containing
peptoids are known to increase membrane permeability and
antibacterial activity. Hence, sequences containing arginine
peptoid monomers were included in the library. This allowed
the comparison of differently functionalised cationic residues
on the peptoid sequences (i.e. the amino NLys peptoids or
the guanidine groups of NhArg). It has also been suggested
that arginine in peptide sequences can improve antibacterial
potency, although this is also linked with enhanced toxic-
ity.26,31 In an attempt to modulate the biological properties
of the peptoid library, for the first time, peptoids with both
lysine and arginine in the same sequence were evaluated
against bacterial targets using the new methodology devel-
oped in our group.42
This sublibrary of peptoids can be split between
sequences exclusively containing arginine residues (peptoids
33–40) and those that contain a mixture of both lysine and
arginine-type side chains (peptoids 41–44). In these com-
pounds NhArg was introduced, which is the equivalent side
chain to the NLys residue, with 4 carbons in the backbone
and the terminal guanidine moiety.
In contrast to peptoids that contain amino-functionalised
NLys residues the NhArg sequences tend to have an increased
toxicity to the mammalian cell lines tested but do also dis-
play improved activity against the bacteria tested. For exam-
ple, when comparing the fluorinated peptoids 36 and 37 to
their lysine-equivalents (24 and 25 respectively) we see an
approximate 2-fold increase in antibacterial activity for all
species tested; for the longest 12-residue sequence
(NxNmfbNmfb)4 activity against E. coli is 13 μM in 36 with
NhArg, compared to 25 μM in 24 (NLys). Against S. aureus
the arginine-type peptoid has an MIC of 2 μM contrasting
with 6 μM for the lysine equivalent. However, in sequences
that were inactive with lysine residues, replacement by NhArg
does not make the sequence active (see peptoid 40, where the
sequence is not active against Gram-negative bacteria at any
concentration), but in these cases the inclusion of the guani-
dine group does increase the toxicity.
As predicted, sequences with a combination of lysine and
arginine-type residues show a balance between toxicity to
mammalian cells and antibacterial activity compared to
sequences containing NLys or NhArg residues exclusively. For
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example, in related peptoids containing all arginine residues
(34), all lysine residues (13) and both lysine/arginine mono-
mers within the same sequence (peptoids 42–44), we see tox-
icity to the HaCaT keratinocytes at 11 μM, 20 μM and 15–33
μM respectively. The general antibacterial activity follows a
similar trend, for example, against E. coli the lysine-only
peptoid 13 has the lowest activity at 25 μM, the arginine-only
peptoid 34 has the most potent activity with an MIC of 6 μM
and the mixed sequences 42–44 have intermediate activity at
17 μM.
The observation that guanidine-only peptoids display the
most potent biological activities is in agreement with previ-
ous studies into arginine-rich peptides, which are able to
bind membrane-bound lipids more readily than their amino-
functionalised lysine equivalents.31,51 In this case it was pro-
posed that the arginine-type side chains can form bidentate
hydrogen bonds with the phospholipid head groups. This
conclusion was also reached in studies with antimicrobial
peptide–peptoid hybrids containing both lysine and
arginine.31,51
Toxicity
From the antibacterial MIC determination in Table 1, multi-
ple promising peptoids were identified that showed little or
no toxicity to either of the mammalian cell lines tested. For
example, compounds 4, 7, 23 and 28 display negligible toxic-
ity to HaCaT or HepG2 at the highest concentrations used
and are also broad spectrum antibacterial agents. However,
many of the sequences generated did display significant
toxicity to mammalian cells, and in general these compounds
were similarly toxic to both HaCaT and HepG2. On the whole,
as the antimicrobial action of a compound increases, the
associated toxicity is also increased. This is a problem found
in other recent studies that focused on the biological applica-
tions of peptoids, however, attention is frequently not
directed towards the issue of toxicity.26,29,37
The selectivity of sequences is highlighted as a particular
challenge for the design of antimicrobial peptoids. To explore
the relationship between activity and toxicity a comparison
was made between the MIC values against each bacterial
species versus the average toxicity of each peptoid to HaCaT
and HepG2 (see Fig. 3).
A handful of peptoids were identified that show respect-
able antibacterial activity and also display low toxicity to
mammalian cells. These compounds have the potential to be
future selective antibiotic compounds. However, a large pro-
portion of the peptoids within this library do display signifi-
cant toxicity. There are also many sequences that are toxic to
mammalian cells, but show little activity against Gram-
negative bacteria. It is likely that the external lipopolysaccha-
ride layer on the outer membrane of both E. coli and
Fig. 3 Antibacterial activity of peptoids plotted against the average toxicity to mammalian cell lines (HaCaT and HepG2). A: E. coli, B:
P. aeruginosa, C: S. aureus, D: S. epidermidis. Compounds indicated in green show activity against prokaryotes with reduced toxicity to eukaryotes,
those in red show increased toxicity to mammalian cells and/or weaker activity against the bacteria.
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P. aeruginosa (absent in Gram positive bacteria) prevents
these peptoids from reaching the cell membrane. To investi-
gate a possible explanation for this observation, the hydro-
phobicity of the compounds was considered.
Hydrophobicity
The hydrophobicity of our library was assessed using reverse-
phase HPLC retention times as in Fig. 4. Although this pro-
vides only a relatively crude measure of hydrophobicity and
may not translate directly into predictions about how a com-
pound will interact with the cell membranes of biological
systems, certain interesting trends were evident from the
analysis.
Since the activity of peptoids is much greater against
Gram-positive bacteria than Gram-negative bacteria, the
graphs are predominantly populated by peptoids for E. coli
and P. aeruginosa due to their higher MIC values. There
appears to be a linear relationship between activity and reten-
tion time for the Gram-positive bacteria, where the peptoids
at longer retention times (therefore more hydrophobic) have
the lowest MIC values against S. aureus or S. epidermidis.
However, for the Gram-negative bacteria, there is no clear
correlation between hydrophobicity and antibacterial activity
of the peptoid library. Some compounds with the longest
retention times (presumably the most hydrophobic) are inac-
tive against these bacteria, whereas others with shorter reten-
tion times display good activity. It has previously been
suggested that highly hydrophobic sequences may have lower
activities due to self-association, preventing sufficient contact
with the cell membrane.29 However, this may be an oversim-
plification since the same results are not observed with
Gram-positive bacteria, where the same hydrophobic peptoid
sequences result in low MIC values.
The discovery that peptoids with high hydrophobicity are
not always the most potent against E. coli and P. aeruginosa,
but against S. aureus a linear relationship is seen between
hydrophobicity and activity is corroborated by a recent
report.29 However, the lack of a consensus between hydro-
phobicity and activity in published libraries, highlights the
need for the research community to develop additional tools
to help predict peptoid properties and likely efficacy.
There also seems to be a correlation between the toxicity
of our peptoid library to mammalian cells and compound
hydrophobicity, with a similar profile of toxicity for both
HaCaT and HepG2 (see Fig. 5). The least hydrophobic com-
pounds are generally the least toxic, whereas those with the
highest retention times show the lowest ED50 values.
Fig. 4 Antibacterial activity of peptoids plotted against HPLC retention times. A: E. coli, B: P. aeruginosa, C: S. aureus, D: S. epidermidis. The HPLC
gradient from 0–100% B was conducted over 30 minutes with a column oven at 40 °C, where solvent A was 95% H2O, 5% MeCN, 0.1% TFA and
solvent B was 95% MeCN, 5% H2O, 0.1% TFA. Peptoids, shown in green, show antibacterial activity, those in black have negligible activity.
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In the literature, HPLC retention times are used to ratio-
nalise antimicrobial activity21,23,29 and also for in silico pre-
dictions of activity.37 From the data presented here, it is
suggested that HPLC retention time alone cannot estimate or
rationalise activity. For Gram-negative bacteria, HPLC reten-
tion time is not predictive of activity and although peptoids
with longer retention times may have an increased efficacy
against Gram-positive bacteria, these compounds may also
have a concomitant and undesirable increased toxicity.
Other parameters to evaluate the activity of antimicrobial
peptoids and guide the design of bioactive peptoids need to
be considered. We recently proposed hydrophobicity
measurements determined via partitioning experiments (i.e.
logD) as an improved approach to rationalise the biological
activity of peptoids.52
Conclusions
This study presents a large and varied library of peptoids that
were specifically designed to mimic natural antimicrobial
peptides. Many of the peptoids generated show potential as
antimicrobial compounds, with broad-spectrum activity
against a wide variety of bacterial and parasitic targets and
may be promising leads in the future for antibiotics that can
combat the increasing problem of resistance.
Most of the peptoids were considerably more active
towards Gram positive species than Gram-negatives in keep-
ing with their differing envelope structures. Hence the
peptoid library has much better therapeutic indices against
S. aureus and S. epidermidis. The best activity against E. coli
reported was 6 μM for peptoids 28, 33, 34, 35 and 37 and 13
μM against P. aeruginosa for peptoids 26, 34 and 36. Many
peptoids also showed micromolar activities against S. aureus
and S. epidermidis with both species showing a similar pat-
tern of sensitivity; S. aureus did show a tendency to be more
resistant than S. epidermidis possibly due to minor differ-
ences in cell surface charge and hydrophobicity.53,54 In many
cases, P. aeruginosa also proved more peptoid-resistant than
E. coli. This difference may reflect variation in lipid composi-
tion or the capacity of P. aeruginosa to form biofilms and has
been observed previously with AMPs, such as LL-37.55
Factors contributing to enhanced antimicrobial activity in-
clude the overall length of sequence, with longer, 12-residue
peptoids typically displaying the best activity, although in
many cases the 9-residue peptoids also display broad spec-
trum activity against bacteria. Substitution of fluorine in
peptoid monomers also enhances activity and in many cases,
achiral sequences displayed potency, especially against the
Gram-positive species. Interestingly, from our library most
compounds that are active against the bacteria but exhibit
no/low toxicity to mammalian cells contain achiral mono-
mers, or at least a reduced frequency of chiral monomers
within the sequence compared to the standard NxNspeNspe
motif. Whether through the presumed increase in hydropho-
bicity, or through other effects, the addition of chiral Nspe
residues in a sequence often has a detrimental effect on over-
all toxicity. Since many of the achiral sequences show potent
antibacterial activity and these peptoids are not expected to
form fully folded peptoid helices, secondary structure is per-
haps not as important as predicted.
It is generally stated that the mode of action for AMPs/
peptoids is cell membrane disruption.47,56,57 For certain com-
pounds, particularly the more hydrophobic compounds that
are both active and toxic, this may be the case. However, the
differences exhibited by some compounds, particularly those
with negligible toxicity to mammalian cells yet good activity
against bacteria, may indicate that cell membrane disruption
is not the only mechanism at work.46 Current work within
our group is now focussing on investigating the molecular
mechanism of a selection of these compounds to elucidate
the factors necessary for antimicrobial selectivity and
potency.
The peptoid community clearly has the requisite tools to
design and synthesise effective antimicrobial peptoid
sequences with potential for clinical application, however,
the challenge now is to focus on increasing pathogen selectiv-
ity while minimising host cell toxicity.
Data availability
In addition to the material provided in the ESI underlying re-
search data for this paper is also available in accordance with
the EPSRC open data policy from doi: 10.15128/r1zg64tk92g.
Experimental
Materials and reagents
Abbreviations for reagents are as follows: tert-butoxycarbonyl
(Boc); 9-fluorenylmethoxylcarbonyl (Fmoc); trifluoroacetic acid
(TFA); triisopropylsilyl (TIPS); N,N-dimethylformamide (DMF);
N,N-diisopropylcarbodiimide (DIC); dimethylsulphoxide (DMSO).
Solvents and reagents were purchased from commercial
Fig. 5 Peptoid toxicity plotted against HPLC retention time. HPLC
gradient from 0–100% B over 30 minutes, column oven at 40 °C,
where solvent A is 95% H2O, 5% MeCN, 0.1% TFA and solvent B is 95%
MeCN, 5% H2O, 0.1% TFA. Compounds indicated by green show
negligible toxicity, those in red show toxicity to mammalian cells.
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sources and used without further purification unless other-
wise stated. Rink amide resin (typical loading level 0.6–0.8
mmol g−1) was purchased from Merck4Biosciences. DMF was
purchased from AGTC Bioproducts (National Diagnostics).
Piperidine, bromoacetic acid and TFA were purchased from
Sigma Aldrich. The amine building blocks were sourced from
Sigma Aldrich or TCI Europe.
Peptoid synthesis procedures
Peptoids in this library were synthesised both manually and
on an automated synthesiser. Protocols for each synthesis
method follow.
Manual linear peptoid synthesis
Fmoc-protected Rink Amide resin (normally 100 mg, 0.1
mmol, typical loading between 0.6–0.8 mmol g−1) was swollen
in DMF (at least 1 h at room temperature, overnight pre-
ferred) in a 20 mL polypropylene Bond Elut SPPS cartridge
fitted with two polyethylene frits (Crawford Scientific). The
resin was deprotected with piperidine (20% in DMF v/v, 2 ×
20 min) and washed with DMF (3 × 2 mL). The resin was
treated with bromoacetic acid (1 mL, 0.6 M in DMF) and DIC
(0.2 mL, 50% v/v in DMF) for 20 min at room temperature on
a shaker platform at 400 rpm (Radleys Technology). The resin
was washed with DMF (3 × 2 mL), before the desired amine
sub-monomer was added (1 mL, 1.5 M in DMF) and allowed
to react for 60 min on the shaker. The resin was again
washed with DMF (3 × 2 mL) and the bromoacetylation and
amine displacement steps were repeated until the final sub-
monomer had been added and the desired peptoid sequence
obtained. Resin was washed with DCM and the final cleavage
from resin was achieved using a TFA cleavage cocktail (4 ml;
TFA : TIPS :H2O, 95 : 2.5 : 2.5) on the shaker at 400 rpm for 60
min. The resin was removed by filtration and the cleavage
cocktail removed in vacuo. The crude product was precipi-
tated in diethyl ether (30 mL) and the precipitate retrieved by
centrifuge for 15 min at 5000 rpm. The ether phase was
decanted and the crude product dissolved in a mixture of
acidified H2O and MeCN and lyophilised to a powder before
purification.
Automated linear peptoid synthesis
Automated peptoid synthesis using an Aapptec Apex 396
synthesiser. Fmoc-protected Rink Amide resin (0.1 mmol,
loading 0.54 mmol g−1) was swollen in DMF (2 mL, 2 min,
475 rpm at RT) and deprotected with 4-methylpiperidine
(20% in DMF v/v, 1 mL for 1 min, 475 rpm at RT; then 2 mL
for 12 min, 475 rpm at RT). The resin was treated with halo-
acetic acid solution (either bromo- or chloroacetic acid, 1 mL,
0.6 M in DMF) and DIC (0.18 mL, 50% v/v in DMF) for
20 min at 475 rpm, RT. The resin was washed with DMF
(2 mL DMF for 1 min at 475 rpm, ×5) before the desired
amine sub-monomer was added (1 mL, 1.5 M in DMF) and
shaken for 60 min at 475 rpm. The resin was washed again
with DMF (2 mL DMF for 1 min at 475 rpm, ×5) and the
acetylation and amine displacement steps were repeated until
the desired sequence was achieved. The resin was shrunk in
diethyl ether and peptoids cleaved off the resin using a TFA
cleavage cocktail (4 ml; TFA : TIPS :H2O, 95 : 2.5 : 2.5) for
30–60 min on an orbital shaker at 250 rpm, RT. The cocktail
was filtered from the resin and evaporated in vacuuo and the
resulting residue precipitated in diethyl ether (∼20 ml).
The crude peptoid was obtained via centrifugation (15 min,
4000 rpm, 5 °C) and the ether layer decanted to yield the
crude product as a powder. Peptoids were lyophilised before
purification by semi-preparative RP-HPLC.
Addition of NhArg and NnArg residues to sequence
To introduce arginine-type residues during the submonomer
procedure, the appropriate unprotected diamine was added
under normal submonomer coupling conditions (1.5 M
amine in DMF, 60 min, room temperature) in place of the
mono N-Boc diamine and the resin washed with DMF (3 ×
2 mL). Dde-OH (10 eq. wrt resin in the minimum volume of
DMF) was added to the resin and placed on the shaker at RT
for 60 min and the resin washed well with DMF (3 × 2 mL).
Subsequent peptoid couplings were made as normal until the
desired sequence was achieved, including any extra Dde-
protected residues.
After synthesis of the linear peptoid sequence, on resin
deprotection of the Dde group was undertaken using 2%
hydrazine in DMF (4 × 4 ml × 3 min) and the resin washed
with DMF (3 × 2 mL). Guanidinylation of the free amines was
achieved using pyrazole-1-carboxamide (6 eq. per free amine,
in the minimum amount of DMF) and DIPEA (6 eq. per free
amine) on the shaker at 400 rpm, RT for 60 min. The resin
was washed with DCM (3 × 2 mL) and shrunk in ether prior
to cleavage from the resin, as above.
Purification by preparative RP-HPLC
Preparative RP-HPLC was performed with a semi-preparative
Perkin Elmer Series 200 lc pump fitted with a 785A UV/vis
detector using a SB-Analytical ODH-S optimal column (250 ×
10 mm, 5 μm); flow rate 2 ml min−1; λ = 250 nm, where a
linear gradient from solvent A to B applied (A = 0.1% TFA in
95% H2O and 5% MeCN, B = 0.1% TFA in 5% H2O and 95%
MeCN).
Characterisation
Peptoids were characterised by accurate LC-MS (QToF mass
spectrometer and an Acquity UPLC from Waters Ltd) using
an Acquity UPLC BEH C8 1.7 μm (2.1 mm × 50 mm) column
with a flow rate of 0.6 ml min−1 and a linear gradient of
5–95% of solvent B over 3.8 min (A = 0.1% formic acid in
H2O, B = 0.1% formic acid in MeCN). Peptide identities were
also confirmed by MALDI-TOF mass spectra analysis
(Autoflex II ToF/ToF mass spectrometer Bruker Daltonik
GmBH) operating in positive ion mode using an α-cyano-4-
hydroxycinnamic acid (CHCA) matrix. Data processing was
done with MestReNova version 8.1.
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Analytical RP-HPLC was carried out using a Perkin Elmer
Series 200 lc pump fitted with a series 200 UV/vis detector
and autosampler using a SB-Analytical ODH-S optimal
column (100 × 1.6 mm, 3.5 μm); flow rate 1 ml min−1; λ =
220 nm, linear gradient elution 0–100% of solvent B over
30 min (A = 0.05% TFA, 95% H2O, 5% MeCN, B = 0.03% TFA,
5% H2O, 95% MeCN).
Biological assays
Antibacterial MIC determination
Please note – ED50, the median effective dose, was defined as
the dose that kills 50% of cells.
Escherichia coli K-12 wild-type strain (W3110/ATCC27325,
F−, λ−, rpoSĲAm), rph-1, InvĲrrnD-rrnE)), Pseudomonas
aeruginosa PA01 (ATCC 15692) Staphylococcus aureus (3R7089
strain Oxford/ATCC9144) and Staphylococcus epidermidis
(laboratory strain from clinical isolate) were selected for
bacteriological studies as representative Gram-negative
(E. coli and P. aeruginosa) and Gram-positive (S. aureus and
S. epidermidis) species. Bacterial cultures were prepared by
streaking bacterial strains onto LB agar plates with an inocu-
lation loop and incubated overnight at 37 °C. A single colony
was selected and placed in 5 mL of Iso-sensitest broth
(Oxoid, ThermoScientific) and incubated with shaking for
16–18 h at 37 °C to provide liquid cultures for testing.
MIC values were obtained according to the protocol de-
scribed by J. M. Andrews et al.58 and were conducted in 96-
well plates (Sarstedt). Bacteria were grown from overnight
cultures in Iso-sensitest broth to an A650nm of 0.07 equivalent
to a 0.5 MacFarland standard (240 μM BaCl2 in 0.18 M
H2SO4). This culture was diluted ten-fold with Iso-sensitest
broth before use. Peptoids were initially dissolved in DMSO
(5 mM) and diluted further in Iso-sensitest broth to achieve a
concentration range of 4–200 μM using 2-fold serial dilu-
tions. 50 μl of inoculum and 50 μl of peptoid solution were
added to each test well (final concentration range of 2–100 μM).
Experiments were performed in triplicate. A positive control
for bacterial growth contained only the inoculum and Iso-
sensitest broth. Other controls contained the inoculum and
serial dilutions of ampicillin (from 250 μg mL−1 to 2 μg
mL−1), serial dilutions of DMSO and the inoculum to confirm
no inhibitory effect on bacterial growth, and Iso-sensitest
broth alone as a sterile control. The MIC was defined as the
lowest concentration which completely inhibited bacterial
growth after incubation at 37 °C for 16 h with shaking. Quan-
titative data was attained from absorbance values using a Bio-
tek Synergy H4 plate reader.
Cytotoxicity assay with HepG2 or HaCaT
Cytotoxicity analyses were performed in 96-well plates
(Costar, Fisher Scientific) using alamarBlue® (Invitrogen) for
cell viability detection using a modified protocol as described
previously. HepG2 or HaCaT cells were subcultured at 37 °C,
5% CO2 in DMEM high glucose supplemented with heat-
inactivated foetal bovine sera (FBS, 10%; Biosera Ltd) and
penicillin/streptomycin (P/S, 1%). Cells were counted using a
Neubauer Improved Haemocytometer. HepG2 cells were
seeded 1 day prior to treatment in 96 well plates at a concen-
tration of 2 × 105 cells per mL in 100 μL of medium (2 × 104
cells per well). Then cells were pre-incubated with the com-
pounds in triplicate in a dilution series in triplicate from 2–
100 μM (5 mM stock solutions in DMSO diluted from 100 μM
to 3 μM; untreated cells with DMSO as a negative control) in
50 μl of the media for 1 hour. Afterwards, 40 μL were re-
moved from each well before the addition of 90 μL of the me-
dia, followed by incubation for 24 hours at 37 °C, 5% CO2.
Then, 10 μL of alamarBlue® (Invitrogen) was added to each
well before a 2 hour incubation prior to assessing cell viabil-
ity using a fluorescent plate reader (Biotek; Ex 560 nm/Em
600 nm). All data were measured in triplicate on a minimum
of two occasions to ensure a robust data set was collected.
The ED50 values were calculated from the dose response re-
sults achieved from the serial dilutions.
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